RemeGen Raises $100M to Advance Potential Lupus Treatment, RC18

RemeGen has received $100 million in private financing to continue advancing RC18 (telitacicept), its lead treatment candidate for autoimmune diseases like systemic lupus erythematosus (SLE) now in a pivotal clinical trial. The funding will also support the China-based company’s early stage treatment discovery platform, help expand its manufacturing…

Lupus: The Invisible Monster

In this animated video from Lupus U.K., the disease is depicted as an invisible monster. It explains that lupus is an autoimmune disease that rarely displays any visible signs. MORE: Discover how lupus affects blood platelets The invisible nature of the disease makes it difficult for non-sufferers to understand just how debilitating lupus…

How to Prevent and Treat Lupus Flares

Lupus is an autoimmune disease where the body attacks healthy tissue. Since lupus affects different areas of the body, there are various symptoms, including joint swelling, rashes, chest pain, fatigue, and light sensitivity. According to Medical News Today, there are a number of ways to help prevent and treat…

Servier and ILTOO Pharma Agree to Develop, Market Lupus Candidate ILT-101

Servier and ILTOO Pharma have joined forces with an exclusive license agreement for the development and commercialization of the investigational drug ILT-101 (low-dose interleukin-2) to target systemic lupus erythematosus (SLE) and other autoimmune diseases. The companies expect that results of the ongoing Phase 2 clinical trial (NCT02955615)…